Programs

A2aR/A2bR antagonist for immuno-oncology

EP4R antagonist for immuno-oncology

First-in-class anti-GPCR antibody for immuno-oncology

mGluR4/7/8 positive allosteric modulator for Parkinson’s disease

NPFFR small molecule antagonist to combat the opioid crisis

Orphan GPCRs for Central Nervous System (CNS) disease area

PAR2 negative allosteric modulator for rare inflammatory diseases

MC4R pharmacochaperone for the treatment of early onset obesity

New GPCRs target identification and validation

First-in-class CXCR4 agonist to control auto-immune diseases

Sema3A fusion protein for immuno-oncology

undisclosed targets